Tarsus Pharmaceuticals

(NASDAQ) TARS

Current Price$59.19

Market Cap$2.55B

Since IPO (2020)+188%

5 Year+75%

1 Year+34%

1 Month-8%

Tarsus Pharmaceuticals Financials at a Glance

Market Cap

$2.55B

Revenue (TTM)

$535.08M

Net Income (TTM)

-$48.27M

EPS (TTM)

-$1.13

P/E Ratio

-52.30

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$59.19

Volume

370,112.515

Open

$60.86

Price

$59.19

Volume

370,112.515

Open

$60.86

Previous Close

$59.28

Daily Range

$58.80 - $62.50

52-Week Range

$38.51 - $85.25

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$59.19

Volume

370,112.515

Open

$60.86

Previous Close

$59.28

Daily Range

$58.80 - $62.50

52-Week Range

$38.51 - $85.25

Estimated Earnings Date

Aug 6, 2026

TARS News

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Jonathan PoncianoMar 24, 2026

Why Shares of Tarsus Pharmaceuticals Are Up Thursday

James HalleyJul 20, 2023

TARS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tarsus Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

370

CEO

Bobak Azamian, MD, PhD

Website

tarsusrx.com

Headquarters

Irvine, CA 92618, US

TARS Financials

Key Financial Metrics (TTM)

Gross Margin

90%

Operating Margin

-9%

Net Income Margin

-9%

Return on Equity

-14%

Return on Capital

-12%

Return on Assets

-8%

Earnings Yield

-1.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.55B

Shares Outstanding

43.02M

Volume

370.11K

Avg. Volume

621.06K

Financials (TTM)

Gross Profit

$420.68M

Operating Income

-$70.97M

EBITDA

-$53.61M

Operating Cash Flow

-$12.45M

Capital Expenditure

-$9.86M

Free Cash Flow

-$22.31M

Cash & ST Invst.

$417.27M

Total Debt

$93.64M

Tarsus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$162.05M

+106.9%

Gross Profit

$152.66M

+108.8%

Gross Margin

94.20%

N/A

Market Cap

$2.55B

N/A

Market Cap/Employee

$7.90M

N/A

Employees

323

N/A

Net Income

-$6.97M

+72.3%

EBITDA

-$5.69M

+74.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$300.06M

-10.6%

Accounts Receivable

$117.21M

+82.7%

Inventory

$4.57M

+69.0%

Long Term Debt

$88.68M

+23.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-8.31%

N/A

Return on Invested Capital

-11.61%

N/A

Free Cash Flow

-$30.47M

-43.4%

Operating Cash Flow

-$24.65M

-19.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IRONDisc Medicine, Inc.

IRONDisc Medicine, Inc.$67.00-5.78%

ARQTArcutis Biotherapeutics, Inc.

ARQTArcutis Biotherapeutics, Inc.$21.23-3.28%

ADPTAdaptive Biotechnologies Corporation

ADPTAdaptive Biotechnologies Corporation$16.90-6.53%

ZLABZai Lab Limited

ZLABZai Lab Limited$16.62-4.15%

AAPGAscentage Pharma Group International

AAPGAscentage Pharma Group International$17.20-5.91%

TVTXTravere Therapeutics, Inc.

TVTXTravere Therapeutics, Inc.$45.81-0.80%

CELCCelcuity Inc.

CELCCelcuity Inc.$88.28-4.53%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

Questions About TARS

What is the current price of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals is trading at $59.28 per share.

What is the 52-week range for Tarsus Pharmaceuticals?

Over the past 52 weeks, Tarsus Pharmaceuticals has traded between $38.51 and $85.25.

How much debt does Tarsus Pharmaceuticals have?

As of the most recent reporting period, Tarsus Pharmaceuticals reported total debt of $88.68M.

How much cash does Tarsus Pharmaceuticals have on hand?

Tarsus Pharmaceuticals reported $102.19M in cash and cash equivalents in its most recent financial results.

What is Tarsus Pharmaceuticals’s dividend yield?

Tarsus Pharmaceuticals does not currently have a dividend yield.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Financials at a Glance

TARS News

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Why Shares of Tarsus Pharmaceuticals Are Up Thursday

TARS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Tarsus Pharmaceuticals

TARS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Tarsus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TARS

What is the current price of Tarsus Pharmaceuticals?

What is the 52-week range for Tarsus Pharmaceuticals?

How much debt does Tarsus Pharmaceuticals have?

How much cash does Tarsus Pharmaceuticals have on hand?

What is Tarsus Pharmaceuticals’s dividend yield?

Premium Investing Services